Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 Ottobre;53(5) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 Ottobre;53(5):503-12

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Periodicità: Trimestrale

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 Ottobre;53(5):503-12

UPDATE ON THE DIAGNOSIS AND TREATMENT OF DIFFERENTIATED THYROID CANCER 

 REVIEW

Diagnostic value of FDG PET/CT imaging

Pace L., Nicolai E., Klain M., Salvatore M.

1 Department of Biomorphological and Functional Sciences, Federico II University, Naples, Italy;
2 Institute of Biostructures and Bioimages, National Council of Research (CNR), Naples, Italy;
3 Institute of Scientific Care and Research (IRCCS), Institute of Nuclear Diagnostics Foundation (SDN),Naples, Italy

Patients with differentiated thyroid cancer (DTC) have a relatively good overall prognosis, but 20% of them develop local recurrences and 10% distant metastases with relatively high mortality (8%). The current prognostic systems lack the ability to predict outcome of patients when discovered to harbor metastases years later. The introduction of 18-F-fluoro-deoxyglucose (FDG) positron emission tomography (PET) and PET/computed tomograohy (CT) for evaluating patients with DTC has added new information on the disease. This review will summarize the data published so far on the use of FDG in DTC. The most appropriate indication to FDG-PET/CT is in evaluating patients with high thyroglobulin level during follow-up, mainly when radioiodine whole body scan is negative. In this setting, a high accuracy has been reported leading to change in management of patients. A clear relationship has been demonstrated between FDG-PET/CT accuracy and thyroglobulin level, with better results obtained in thyroid stimulating hormone (TSH) stimulated condition. Moreover, FDG imaging provides potentially relevant information on tumour biology, and scan results may enable to prognostically stratify DTC patients with local or distant recurrences. Based on literature data, FDG-PET/CT does not have routine clinical indication in the initial staging of DTC patients, as well as in evaluating cytologically indeterminated thyroid nodules.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina